24764-97-4

Basic information

• Product Name: 2-bromo-butyraldehyde
• Synonyms: 2-bromo-butyraldehyde;2-BroMobutanal
• CAS NO: 24764-97-4
• Molecular Formula: C₄H₇BrO
• Molecular Weight: 151.00178
• Mol File: 24764-97-4.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 235°C (rough estimate)
• Appearance: /
• Density: 1.4690
• Refractive Index: 1.4683
• CAS DataBase Reference: 2-bromo-butyraldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-butyraldehyde(24764-97-4)
• EPA Substance Registry System: 2-bromo-butyraldehyde(24764-97-4)

Safety Data

• Hazardous Substances Data: 24764-97-4(Hazardous Substances Data)

Usage

Description

2-bromo-butyraldehyde, also known as 2-bromobutanal, is a chemical compound with the formula C4H7BrO. It is a colorless liquid with a pungent odor and is commonly used as a building block in organic synthesis.

Uses

Used in Pharmaceutical Industry:
2-bromo-butyraldehyde is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving the efficacy of existing medications.
Used in Pesticide Industry:
2-bromo-butyraldehyde is used as a precursor in the production of pesticides, helping to create effective and safer agrochemicals for agricultural applications.
Used in Fine Chemicals Industry:
2-bromo-butyraldehyde is used as an intermediate in the synthesis of other fine chemicals, playing a crucial role in the production of specialty chemicals for various applications.
Used in Fragrance and Flavoring Industry:
2-bromo-butyraldehyde is used as a building block in the synthesis of fragrances and flavoring compounds, enhancing the variety and quality of scents and tastes in consumer products.
Used in Plastics Industry:
2-bromo-butyraldehyde is used in the manufacturing of plastics, contributing to the development of new plastic materials with improved properties.
Used in Dyes Industry:
2-bromo-butyraldehyde is used in the production of dyes, playing a role in creating a wide range of colorants for various applications.
Used in Rubber Chemicals Industry:
2-bromo-butyraldehyde is used in the manufacturing of rubber chemicals, aiding in the development of rubber products with enhanced performance characteristics.

Upstream product

• 14548-12-0 1-Dimethylamino-1-buten 
• 4461-87-4 1,1-dimethoxybutane 
• 868-36-0 2-bromobutanal dimethyl acetal 
• 511-67-1 5,5-dibromobarbituric acid 
• 123-72-8 butyraldehyde 
• 60-29-7 diethyl ether 
• 4275-07-4 N-butylideneaniline 
• 7726-95-6 bromine 
• 71-43-2 benzene 
• 7707-71-3 butylidene-propyl-amine 
• 56249-61-7 N-butylidenebenzylamine 
• 67-66-3 chloroform 
• 61759-12-4 2-phenylselanylbutanal 
• 39583-28-3 2-ethyl-3-nitro-oxirane 

Downstream Products

• 17626-73-2 5-ethylthiazole 
• 64689-43-6 (Z)-4-Bromo-1-(4-fluoro-phenyl)-hex-2-en-1-one 
• 10045-49-5 5-ethyl-2-phenylthiazole 
• 901304-49-2 C₂₀H₂₃N₃OS 
• 15729-76-7 2,5-diethylthiazole 
• 130570-57-9 4-benzyloxy-2,3-dimethyl-7-methoxyindole 
• 39136-60-2 5-ethylthiazol-2-amine 
• 35874-97-6 α-(phenylthio)butanal 
• 80387-13-9 2-(benzoyloxy)butanal 
• 7422-95-9 1-dimethylamino-1-aza-1,3-pentadiene 
• 92722-12-8 4-amino-N-(5-ethyl-oxazol-2-yl)-benzenesulfonamide 
• 7472-25-5 1,1-dimethoxy-butan-2-ol 
• 19961-52-5 5-ethyl-2-methylthiazole 

Relevant articles and documents

Catalytic Diastereoselective Hetero-Diels-Alder Reaction of α-Haloacroleins with Alkenes: Construction of 3,4-Dihydropyran

In this Letter, a catalytic diastereoselective hetero-Diels-Alder reaction of α-haloacroleins with less polarized alkenes was developed, and the resulting 3,4-dihydropyrans were produced in high yields with a broad substate scope. Mechanism studies showed that 3,4-dihydropyran was produced from the ring expansion of cyclobutane, which was generated in the ring contraction of the initially formed unstable 3,4-dihydropyran conformer.

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

Thiazole derivatives

The invention provides compounds of formula 1 wherein R1, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are described. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.